Clinical Trials
47 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
MK-3475-G21
Merck Sharp & Dohme LLC
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
PRIMAVERA
AstraZeneca
MK-3475-051
Merck Sharp & Dohme LLC
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
DAHLIA
Recursion Pharmaceuticals Inc.
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
OPAL
AVM Biotechnology Inc
QUADvance
AvenCell Therapeutics, Inc.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
CAVALRY
University of Chicago
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
SELECT-CAR-NK
Essen Biotech
PlaTform
The Lymphoma Academic Research Organisation
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Sheba Medical Center
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Chinese PLA General Hospital
ANXIN-02
The Second Hospital of Anhui Medical University
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
STARLIGHT-1
Estrella Immunopharma, Inc.
BAH2573-103
Essen Biotech
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
CytosinLab Therapeutics Co., Ltd.
CAR-NK
Shanghai Tongji Hospital, Tongji University School of Medicine
CAR-T
Tianjin Medical University General Hospital
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Zhujiang Hospital
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CARTHEDRALL
University of Sao Paulo
MZL-001
The First Hospital of Jilin University
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Tyligand Bioscience (Shanghai) Limited
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Chinese PLA General Hospital